Eko Raises $41 Million in Series D

Eko Health has raised $41 million in Series D financing with participation from ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital.
 
The San Francisco, Calif.-based company said the funding round will be used to grow U.S. and global access to the company’s early disease detection platform. The new capital aims to deepen Eko’s U.S. presence and accelerate expansion into key international markets, supported by investments from Double Point Ventures in the U.S., Singapore-based global investor EDBI, and LG Technology Ventures, backed by the LG Group of South Korea.
 
The funding follows U.S. Food and Drug Administration (FDA) clearances for Eko’s structural heart murmur and low ejection fraction (Low EF) detection algorithms.
 
The murmur algorithm was validated in a Massachusetts General Hospital study, showing double the identification rates of structural heart murmurs compared to conventional practice in primary care. The low EF algorithm, developed with Mayo Clinic, was demonstrated in an Imperial College London study to “significantly enhance” identifying heart failure with reduced ejection fraction in GP clinics.
 
Eko’s platform hopes to reduce diagnostic bottlenecks, leading to earlier interventions and improved outcomes.
 
“Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere,” said Connor Landgraf, CEO and co-founder of Eko Health. “Just as Ring transformed doorbells into home security systems, Eko has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices.”
 
“Eko has spent the past decade building an unparalleled dataset of digital heart and lung sounds, which it leverages to develop clinical AI for the physical world,” added Vas Bailey, Ph.D., chair of the board at Eko Health and partner at ARTIS Ventures. “Like countless others, I lost a parent much too early to undetected heart disease. I am deeply inspired by the team’s dedication to saving lives by equipping hundreds of thousands—and soon millions—of clinicians worldwide with our groundbreaking early detection platform.”